Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.54 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.54 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.54 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.54 |
| ▸ | GAPDH | P04406 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | STAT6 | P42226 | 1/20 | 0.54 |
| ▸ | PI4KA | P42356 | 1/20 | 0.54 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.54 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.54 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14243961 | 1.00 | MEN1 (0.63) | MEN1KMT2AADORA3ADORA1ADORA2A | |
| SCHEMBL19502714 | 1.00 | MEN1 (0.63) | MEN1KMT2AADORA3ADORA1ADORA2A | |
| SCHEMBL29389308 | 1.00 | MEN1 (0.63) | MEN1KMT2AADORA3ADORA1ADORA2A | |
| SCHEMBL3150637 | 0.88 | ADORA2A (0.69) | MEN1KMT2AADORA3ADORA1ADORA2A | |
| SCHEMBL20579764 | 0.88 | ADORA2A (0.69) | MEN1KMT2AADORA3ADORA1ADORA2A | |
| SCHEMBL29435131 | 0.88 | ADORA2A (0.69) | MEN1KMT2AADORA3ADORA1ADORA2A | |
| SCHEMBL1996593 | 0.88 | ADORA2A (0.69) | MEN1KMT2AADORA3ADORA1ADORA2A | |
| SCHEMBL18486352 | 0.88 | ADORA2A (0.69) | MEN1KMT2AADORA3ADORA1ADORA2A | |
| SCHEMBL157531 | 0.88 | ADORA2A (0.69) | MEN1KMT2AADORA3ADORA1ADORA2A | |
| SCHEMBL29390532 | 0.88 | ADORA2A (0.69) | MEN1KMT2AADORA3ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1329 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634380-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| WO-2025137275-A1 | NOVEL CAS NUCLEASES AND POLYNUCLEOTIDES ENCODING THE SAME | MODERNATX, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| US-20240363254-A1 | METHOD FOR CHARACTERIZING A TUMOUR | UNIVERSITÉ DE MONTPELLIER (FR) | 2024-10-31 | — | — | US | claimed |
| WO-2024129779-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | MODERNATX, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| EP-4379052-A2 | MRNA PURIFICATION BY TANGENTIAL FLOW FILTRATION | Ethris GmbH (DE) | 2024-06-05 | — | — | EP | claimed |
| EP-3460064-B1 | EFFICIENT PROTEIN EXPRESSION IN VIVO USING MODIFIED RNA (MOD-RNA) | THE GENERAL HOSPITAL CORP D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2023215498-A2 | COMPOSITIONS AND METHODS FOR CD28 ANTAGONISM | MODERNATX, INC. (US) | 2023-11-09 | — | — | WO | claimed |
| EP-4271389-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2023-11-08 | — | — | EP | claimed |
| WO-2022147039-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES INC. (US) | 2022-07-07 | — | — | WO | claimed |
| US-20190175690-A1 | COMPOSITIONS AND METHODS FOR CARDIAC REPAIR | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2019-06-13 | — | — | US | claimed |
| EP-3460064-A1 | EFFICIENT PROTEIN EXPRESSION IN VIVO USING MODIFIED RNA (MOD-RNA) | The General Hospital Corporation d/b/a Massachusetts General Hospital (US) | 2019-03-27 | — | — | EP | claimed |
| US-10086043-B2 | Efficient protein expression in vivo using modified RNA (MOD-RNA) | THE GENERAL HOSPITAL CORPORATION (US) | 2018-10-02 | — | — | US | claimed |
| EP-2694660-B1 | EFFICIENT PROTEIN EXPRESSION IN VIVO USING MODIFIED RNA (MOD-RNA) | MASSACHUSETTS GEN HOSPITAL (US) | 2018-08-08 | — | — | EP | claimed |
| US-20140073687-A1 | EFFICIENT PROTEIN EXPRESSION IN VIVO USING MODIFIED RNA (MOD-RNA) | IMMUNE DISEASE INSTITUTE, INC. (US) | 2014-03-13 | — | — | US | claimed |
| US-20260146262-A1 | METHODS OF LIPID NANOPARTICLE PRODUCTION IN CROSS-MIXERS | MODERNATX, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4746905-A1 | RSV VACCINE | Astrazeneca AB (SE) | 2026-05-27 | — | — | EP | disclosed |
| US-20120322864-A1 | SUSTAINED POLYPEPTIDE EXPRESSION FROM SYNTHETIC, MODIFIED RNAS AND USES THEREOF | IMMUNE DISEASE INSTITUTE, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120046346-A1 | SUSTAINED POLYPEPTIDE EXPRESSION FROM SYNTHETIC, MODIFIED RNAS AND USES THEREOF | IMMUNE DISEASE INSTITUTE, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2011130624-A2 | SUSTAINED POLYPEPTIDE EXPRESSION FROM SYNTHETIC, MODIFIED RNAS AND USES THEREOF | IMMUNE DISEASE INSTITUTE, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | RNASE1, POLRMT, TERT | MEN1 4242/4885KMT2A 2441/4885ADORA3 4335/4885 |
| US-20190175690-A1 | COMPOSITIONS AND METHODS FOR CARDIAC REPAIR | YAP1, TNNI3, FABP3 | MEN1 4403/4885KMT2A 1996/4885ADORA3 4202/4885 |
| US-20260146262-A1 | METHODS OF LIPID NANOPARTICLE PRODUCTION IN CROSS-MIXERS | ELAVL1, IGF2BP2, FUS | MEN1 3907/4885KMT2A 3684/4885ADORA3 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.